Published in Br J Clin Pharmacol on December 29, 2015
Crosstalk between Long Noncoding RNAs and MicroRNAs in Health and Disease. Int J Mol Sci (2016) 0.85
Erythropoietin and mTOR: A "One-Two Punch" for Aging-Related Disorders Accompanied by Enhanced Life Expectancy. Curr Neurovasc Res (2016) 0.75
Mechanistic target of rapamycin modulation: an emerging therapeutic approach in a wide variety of disease processes. Br J Clin Pharmacol (2016) 0.75
VAMP3 and SNAP23 mediate the disturbed flow-induced endothelial microRNA secretion and smooth muscle hyperplasia. Proc Natl Acad Sci U S A (2017) 0.75
Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med (2005) 28.21
Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation (2013) 28.02
Progress and challenges in translating the biology of atherosclerosis. Nature (2011) 9.41
mTOR signaling at a glance. J Cell Sci (2009) 8.66
Macrophages in the pathogenesis of atherosclerosis. Cell (2011) 7.78
Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell (2010) 7.59
mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex. Nature (2007) 7.12
Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science (2012) 6.69
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med (2015) 6.12
Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med (2015) 5.59
Atherosclerosis: current pathogenesis and therapeutic options. Nat Med (2011) 4.95
Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol (2009) 4.66
Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation (2003) 4.61
A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem Soc Trans (2009) 4.37
Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov (2011) 4.05
Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet (2015) 3.75
Nutrients suppress phosphatidylinositol 3-kinase/Akt signaling via raptor-dependent mTOR-mediated insulin receptor substrate 1 phosphorylation. Mol Cell Biol (2006) 3.67
A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet (2009) 3.55
An emerging role of mTOR in lipid biosynthesis. Curr Biol (2009) 3.50
Identification of IRS-1 Ser-1101 as a target of S6K1 in nutrient- and obesity-induced insulin resistance. Proc Natl Acad Sci U S A (2007) 3.32
Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med (2010) 3.27
Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest (2011) 3.00
Dissecting the role of mTOR: lessons from mTOR inhibitors. Biochim Biophys Acta (2009) 2.89
mTOR complex 2 signaling and functions. Cell Cycle (2011) 2.66
Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue. Diabetes (2010) 2.65
Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res (2004) 2.64
Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discov Today (2006) 2.59
mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling. Mol Cell Biol (2009) 2.57
Macrophage autophagy plays a protective role in advanced atherosclerosis. Cell Metab (2012) 2.48
Monocyte and macrophage dynamics during atherogenesis. Arterioscler Thromb Vasc Biol (2011) 2.44
Neovascularization in human atherosclerosis. Circulation (2006) 2.44
AMPK, insulin resistance, and the metabolic syndrome. J Clin Invest (2013) 2.44
Autophagy regulates cholesterol efflux from macrophage foam cells via lysosomal acid lipase. Cell Metab (2011) 2.41
Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur Heart J (2005) 2.40
Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. Circulation (2004) 2.30
Plaque neovascularization and antiangiogenic therapy for atherosclerosis. J Am Coll Cardiol (2007) 2.27
Differential clinical responses to everolimus-eluting and Paclitaxel-eluting coronary stents in patients with and without diabetes mellitus. Circulation (2011) 2.17
Rapalogs and mTOR inhibitors as anti-aging therapeutics. J Clin Invest (2013) 2.14
Effects of metformin on metabolite profiles and LDL cholesterol in patients with type 2 diabetes. Diabetes Care (2015) 2.13
Role of angiogenesis in cardiovascular disease: a critical appraisal. Circulation (2005) 2.13
Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med (2014) 2.09
mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation. Cell Metab (2013) 1.91
Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. Cancer Res (2010) 1.86
Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells. Gastroenterology (2012) 1.77
Mechanisms and consequences of efferocytosis in advanced atherosclerosis. J Leukoc Biol (2009) 1.76
Targeting PI3 kinase/AKT/mTOR signaling in cancer. Crit Rev Oncog (2012) 1.71
Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells. Sci Rep (2012) 1.66
Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients. Clin Cancer Res (2012) 1.63
A Central role for mTOR in lipid homeostasis. Cell Metab (2013) 1.57
Statins, autophagy and cancer metastasis. Int J Biochem Cell Biol (2012) 1.56
Statins activate AMP-activated protein kinase in vitro and in vivo. Circulation (2006) 1.55
Rapamycin and mTOR kinase inhibitors. J Chem Biol (2008) 1.51
Molecular biology of atherosclerosis. Physiol Rev (2013) 1.49
The mammalian target of rapamycin signalling pathway is involved in osteoblastic differentiation of vascular smooth muscle cells. Can J Cardiol (2013) 1.48
Oral rapamycin after coronary bare-metal stent implantation to prevent restenosis: the Prospective, Randomized Oral Rapamycin in Argentina (ORAR II) Study. J Am Coll Cardiol (2006) 1.46
All roads lead to mTOR: integrating inflammation and tumor angiogenesis. Cell Cycle (2007) 1.38
Inhibition of autophagy enhances anticancer effects of atorvastatin in digestive malignancies. Cancer Res (2010) 1.34
The role of monocytes in angiogenesis and atherosclerosis. J Am Coll Cardiol (2013) 1.32
Chronic mTOR inhibition by rapamycin induces muscle insulin resistance despite weight loss in rats. Br J Pharmacol (2012) 1.32
Metformin: an old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr (2013) 1.31
Selective clearance of macrophages in atherosclerotic plaques by autophagy. J Am Coll Cardiol (2007) 1.31
Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR-/- mice despite severe hypercholesterolemia. Atherosclerosis (2007) 1.29
Novel concepts in atherogenesis: angiogenesis and hypoxia in atherosclerosis. J Pathol (2009) 1.27
Has our understanding of calcification in human coronary atherosclerosis progressed? Arterioscler Thromb Vasc Biol (2014) 1.27
Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients. Am J Transplant (2008) 1.27
Dynamics of vessel wall changes following the implantation of the absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months. EuroIntervention (2014) 1.26
Chronic inhibition of mammalian target of rapamycin signaling downregulates insulin receptor substrates 1 and 2 and AKT activation: A crossroad between cancer and diabetes? J Am Soc Nephrol (2006) 1.24
Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo. Mol Cancer (2010) 1.21
Review series: TOR kinase complexes and cell migration. J Cell Biol (2011) 1.19
Rapamycin attenuates atherosclerotic plaque progression in apolipoprotein E knockout mice: inhibitory effect on monocyte chemotaxis. J Cardiovasc Pharmacol (2005) 1.18
Adverse events associated with mTOR inhibitors. Expert Opin Drug Saf (2012) 1.17
Regulation of hepatic LDL receptors by mTORC1 and PCSK9 in mice. J Clin Invest (2012) 1.14
Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V). Vasc Health Risk Manag (2008) 1.12
Recent clinical trials of mTOR-targeted cancer therapies. Rev Recent Clin Trials (2011) 1.12
Protective effect of the immunosuppressant sirolimus against aortic atherosclerosis in apo E-deficient mice. Am J Transplant (2003) 1.10
The integral role of mTOR in lipid metabolism. Cell Cycle (2011) 1.10
Diabetes and atherosclerosis: is there a role for hyperglycemia? J Lipid Res (2008) 1.09
Degree of carotid plaque calcification in relation to symptomatic outcome and plaque inflammation. J Vasc Surg (2004) 1.08
Strategies for the management of adverse events associated with mTOR inhibitors. Transplant Rev (Orlando) (2014) 1.07
Tailoring mTOR-based therapy: molecular evidence and clinical challenges. Pharmacogenomics (2013) 1.05
Rapamycin attenuates atherosclerosis induced by dietary cholesterol in apolipoprotein-deficient mice through a p27 Kip1 -independent pathway. Atherosclerosis (2004) 1.05
Mammalian target of rapamycin complex 1 (mTORC1) and 2 (mTORC2) control the dendritic arbor morphology of hippocampal neurons. J Biol Chem (2012) 1.04
HIF-1 alpha expression is associated with an atheromatous inflammatory plaque phenotype and upregulated in activated macrophages. Atherosclerosis (2007) 1.04
Why does diabetes increase atherosclerosis? I don't know! J Clin Invest (2004) 1.04
TOR-centric view on insulin resistance and diabetic complications: perspective for endocrinologists and gerontologists. Cell Death Dis (2013) 1.04
Rapamycin has a biphasic effect on insulin sensitivity in C2C12 myotubes due to sequential disruption of mTORC1 and mTORC2. Front Genet (2012) 1.03
Rapamycin-mediated mTORC2 inhibition is determined by the relative expression of FK506-binding proteins. Aging Cell (2015) 1.03
Disruption of mammalian target of rapamycin complex 1 in macrophages decreases chemokine gene expression and atherosclerosis. Circ Res (2014) 1.00
Cardiovascular disease and mTOR signaling. Trends Cardiovasc Med (2011) 1.00
Macrophage autophagy in atherosclerosis. Mediators Inflamm (2013) 1.00
mTOR inhibitors in renal cell carcinoma. Therapy (2011) 1.00
Oral rapamycin attenuates inflammation and enhances stability of atherosclerotic plaques in rabbits independent of serum lipid levels. Br J Pharmacol (2009) 0.99
Therapeutic strategy targeting the mTOR-HIF-1alpha-VEGF pathway in ovarian clear cell adenocarcinoma. Pathol Int (2009) 0.99
The rapamycin-binding domain of the protein kinase mammalian target of rapamycin is a destabilizing domain. J Biol Chem (2007) 0.99
Mammalian target of rapamycin (mTOR) inhibition with rapamycin improves cardiac function in type 2 diabetic mice: potential role of attenuated oxidative stress and altered contractile protein expression. J Biol Chem (2013) 0.96
Autophagy in vascular disease. Circ Res (2015) 0.95
The cdk1-cyclin B complex is involved in everolimus triggered resistance in the PC3 prostate cancer cell line. Cancer Lett (2011) 0.95
Acetylation of histone H3 prevents resistance development caused by chronic mTOR inhibition in renal cell carcinoma cells. Cancer Lett (2012) 0.95
Rapamycin eluting stent: the onset of a new era in interventional cardiology. Heart (2002) 0.94
mTOR inhibition: a promising strategy for stabilization of atherosclerotic plaques. Atherosclerosis (2014) 0.94
Elastin fragmentation in atherosclerotic mice leads to intraplaque neovascularization, plaque rupture, myocardial infarction, stroke, and sudden death. Eur Heart J (2014) 0.88
Methods to assess autophagy in situ--transmission electron microscopy versus immunohistochemistry. Methods Enzymol (2014) 0.84
Cholesterol-independent effects of atorvastatin prevent cardiovascular morbidity and mortality in a mouse model of atherosclerotic plaque rupture. Vascul Pharmacol (2016) 0.78
Defective autophagy in vascular smooth muscle cells alters contractility and Ca²⁺ homeostasis in mice. Am J Physiol Heart Circ Physiol (2015) 0.78
The Dipeptidyl Peptidases 4, 8, and 9 in Mouse Monocytes and Macrophages: DPP8/9 Inhibition Attenuates M1 Macrophage Activation in Mice. Inflammation (2016) 0.77
Spermidine reduces lipid accumulation and necrotic core formation in atherosclerotic plaques via induction of autophagy. Atherosclerosis (2016) 0.77
NecroX-7 reduces necrotic core formation in atherosclerotic plaques of Apoe knockout mice. Atherosclerosis (2016) 0.76
Chronic intermittent mental stress promotes atherosclerotic plaque vulnerability, myocardial infarction and sudden death in mice. Atherosclerosis (2015) 0.75
mTOR Inhibition & Cardiovascular Diseases: Dyslipidemia and Atherosclerosis. Transplantation (2017) 0.75